Posted by Michael Wonder on 06 Sep 2018
ITF Pharma announces FDA approval of Tiglutik (riluzole) oral suspension for the treatment of amyotrophic lateral sclerosis
6 September 2018 - Tiglutik, the first and only easy-to-swallow thickened riluzole liquid for ALS, will be commercially available mid-October of 2018.
ITF Pharma announced today that the U.S. FDA has approved Tiglutik (riluzole) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS).
Tiglutik is the first and only easy-to-swallow thickened riluzole liquid for ALS and is administered twice daily via an oral syringe.
